Immunovaccine Inc.

Immunovaccine Inc.

November 01, 2011 09:07 ET

Immunovaccine to Report Q3 2011 Financial Results and Conference Call

HALIFAX, NOVA SCOTIA--(Marketwire - Nov. 1, 2011) - Immunovaccine Inc. (TSX VENTURE:IMV) will release its third quarter 2011 financials on November 8, 2011, after markets close. The announcement will be followed by a webcast and conference call, hosted by John Trizzino, Chief Executive Officer, and other members of senior management on November 9, 2011, at 10:00 am Eastern Time (11:00 am AT).

All interested parties can join the call by dialing 1-888-231-8191 or 647-427-7450. Please dial in 15 minutes prior to the start of the call. The conference call will also be available by webcast live and available for replay at for 90 days.

About Immunovaccine

Immunovaccine Inc. develops vaccines formulated in its vaccine delivery platform for cancer therapy and infectious disease. The Company's DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has taken its platform technology and proprietary cancer vaccine into phase I human trials and has demonstrated its safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Pfizer Animal Health has licensed the Company's delivery technology platform to develop vaccines for livestock. Connect at or

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information